363 related articles for article (PubMed ID: 24613528)
1. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Schutz FA; Buzaid AC; Sartor O
Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
[TBL] [Abstract][Full Text] [Related]
2. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
3. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
Ecstein-Fraisse E; Su Z
Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
[TBL] [Abstract][Full Text] [Related]
4. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
6. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
7. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
9. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
[TBL] [Abstract][Full Text] [Related]
10. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Coenen JLLM; van den Berg HPP; Mehra N; van Oort IM; Fossion LMCL; Hendriks MP; Bloemendal HJ; van de Luijtgaarden ACM; Ten Bokkel Huinink D; van den Bergh ACMF; van den Bosch J; Polee MB; Weijl N; Bergman AM; Uyl-de Groot CA; Gerritsen WR
Clin Genitourin Cancer; 2019 Oct; 17(5):e946-e956. PubMed ID: 31439536
[TBL] [Abstract][Full Text] [Related]
11. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
13. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Nozawa M; Mukai H; Takahashi S; Uemura H; Kosaka T; Onozawa Y; Miyazaki J; Suzuki K; Okihara K; Arai Y; Kamba T; Kato M; Nakai Y; Furuse H; Kume H; Ide H; Kitamura H; Yokomizo A; Kimura T; Tomita Y; Ohno K; Kakehi Y
Int J Clin Oncol; 2015 Oct; 20(5):1026-34. PubMed ID: 25809824
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Francini E; Fiaschi AI; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):884-7. PubMed ID: 26053281
[TBL] [Abstract][Full Text] [Related]
15. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
16. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Singal R; Ramachandran K; Gordian E; Quintero C; Zhao W; Reis IM
Clin Genitourin Cancer; 2015 Feb; 13(1):22-31. PubMed ID: 25178642
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
Horgan AM; Seruga B; Pond GR; Alibhai SM; Amir E; De Wit R; Eisenberger MA; Tannock IF
J Geriatr Oncol; 2014 Apr; 5(2):119-26. PubMed ID: 24495703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]